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Background: Newborns and young infants suffer high rates of infections
in South Asia and sub-Saharan Africa. Timely access to appropriate antibiotic therapy is essential for reducing mortality. In an effort to develop
community case management guidelines for young infants, 0–59 days old,
with clinically diagnosed severe infections, or with fast breathing, 4 trials
of simplified antibiotic therapy delivered in primary care clinics (Pakistan,
Democratic Republic of Congo, Kenya and Nigeria) or at home (Bangladesh and Nigeria) are being conducted.
Methods: This article describes the scientific rationale for these trials,
which share major elements of trial design. All the trials are in settings of
high neonatal mortality, where hospitalization is not feasible or frequently
refused. All use procaine penicillin and gentamicin intramuscular injections
for 7 days as reference therapy and compare this to various experimental
arms utilizing comparatively simpler combination regimens with fewer
injections and oral amoxicillin.
Conclusion: The results of these trials will inform World Health Organization policy regarding community case management of young infants with
clinical severe infections or with fast breathing.
Key Words: newborn, young infant, sepsis, pneumonia, meningitis, clinically severe infections, fast breathing, community management, community
case management, antibiotic, gentamicin, amoxicillin, procaine penicillin,
South Asia, sub-Saharan Africa
(Pediatr Infect Dis J 2013;32:S7–S11)

I

nfections in the neonatal period are responsible for an estimated
12% of under-5 child mortality.1 Most newborns with severe infections (sepsis, pneumonia, meningitis) in South Asia and sub-Saharan
Africa die without access to hospitalization and appropriate therapy,2–6
prompting the need for alternative strategies for home or first-level
facility-based management in countries with a high burden of neonatal deaths.3–5,7 This article describes the scientific rationale for the
study design of 3 randomized controlled equivalence trials evaluating
simplified antibiotic regimens for management of clinically diagnosed
severe infections in newborns and young infants in community settings
in Bangladesh, Pakistan and a multicountry study in Africa (Democratic Republic of Congo, Kenya and Nigeria). Additionally, the scientific reasoning underlying a trial of simplified antibiotic therapy for
management of young infants who present with fast breathing alone
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is also described. Although the individual study designs are adapted
to site and country needs and are detailed in the site-specific methods articles,8–11 here we focus on the overarching scientific approach to
case definitions, selection of trial sites, participant inclusion/exclusion
criteria, choice of antibiotics and regimens and outcomes. The common design elements were made possible by extensive collaboration
between the study sponsors12 and investigators and will enhance the
interpretation and application of the studies’ results, in part by enabling
future pooled analyses for outcomes of subgroups of interest (eg, treatment failure in newborns with early-onset infections, newborns with
multiple clinical signs of illness vs. single signs, etc.).

STUDY AGE GROUP
Newborns have increased vulnerability to infection-related
morbidity and mortality because of their immature immune systems
and underdeveloped skin barrier.13 However, a decision to include
infants beyond the newborn period, that is, in the second month of
life, was made for 2 reasons. First, the newborn immune response
matures on a gradient with age14 with increased susceptibility to
infection persisting into the second month of life, and second, the
current World Health Organization (WHO)/United Nations International Children’s Emergency Fund Integrated Management of
Childhood Illness addresses children aged 0–59 days as a separate
group (“young infants”) from children 2–59 months old.15 Therefore, any new case management strategy for use in developing countries needs to be applicable to infants who are 0–59 days old.

DIAGNOSTIC ALGORITHM TO STANDARDIZE
DEFINITION OF CLINICALLY DIAGNOSED SEVERE
INFECTIONS IN NEWBORNS AND YOUNG
INFANTS ACROSS THE TRIAL SITES
Infections in the newborn and young infant present with
nonspecific signs and symptoms and can be difficult to diagnose
even by experienced health professionals.13 A high index of suspicion and prompt initiation of antibiotic therapy are required to
save lives because of the often rapidly fulminant course of invasive
bacterial infections in young infants. This practice is followed in
industrialized countries where clinically ill-appearing newborns
and young infants are treated with parenteral antibiotics on the
basis of a diagnosis of “presumed sepsis,” although blood cultures
eventually are found to yield no growth in the vast majority.8,16–18
In an effort to promote the early detection and appropriate referral of sick young infants by frontline health workers in
resource-limited settings, WHO, United States Agency for International Development and the Saving Newborn Lives Initiative of
Save the Children (funded by the Bill and Melinda Gates Foundation) sponsored a multicountry study to evaluate several clinical
signs for their utility in making referral decisions compared with
the judgment of an experienced clinician.19 Participating countries included Bangladesh, Bolivia, Ghana, India, Pakistan and
South Africa. The Young Infant Clinical Signs Study resulted in
the development of a simple clinical algorithm based on 7 signs
and symptoms for predicting severe illness in the young infant
with high sensitivity and moderate specificity for use in first-level
health facilities.19 The 7 clinical signs and symptoms are history
of difficulty feeding, history of convulsions, movement only when
stimulated, respiratory rate of 60 breaths per minute or more, severe
chest indrawing, temperature of 37.5°C or more or less than 35.5°C.
The presence of any one triggers a decision to refer the infant. The
availability of the validated Young Infant Clinical Signs of Severe
Illness algorithm presented an evidence-based starting point for the
development of a clinical definition of severe infection in the young
infant for use in the proposed trials. However, certain limitations of
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this algorithm influence specificity for the diagnosis of infection,
considerations that are important in equivalence trial settings where
a nonspecific definition of infection could dilute out important differences in therapeutic options among a smaller group of infants
who truly had severe bacterial infections included within a larger
group of mildly ill infants who would recover without antibiotic
therapy. In order to increase specificity of diagnosis of clinically
diagnosed severe infection, the following modifications have been
made: the fast respiratory rate sign has been dropped from our case
definition as accumulating evidence indicates that it substantively
reduces specificity of the case definition (see discussion below),
the upper temperature cutoff (for fever) has been increased to 38°C
(instead of 37.5°C) and history of difficulty feeding requires confirmation by observation of infant feeding (African sites) or determination of poor suck through digital examination if feeding cannot
be observed (Asian sites). Presence of convulsions is considered to
indicate critical illness, and infants with convulsions are excluded.
Table 1 presents the case definition used for diagnosis of clinical
severe infections in these trials.
Fast breathing (respiratory rate >60 per minutes) is frequently
present as an isolated sign in young infants who do not otherwise appear
ill.19 Fast breathing did not predict mortality in young infants in studies
from Bangladesh and India.20–22 However, fast breathing even as a single
sign is part of the WHO Integrated Management of Childhood Illness
clinical algorithm and indicates very severe disease and need for hospital referral and parenteral antibiotics.23 This has created a management
dilemma, whether to treat young infants with fast breathing alone as
a mild illness or as a severe illness. In some settings from South Asia,
neonates and young infants with fast breathing have been successfully
treated by oral antibiotics.6,24,25 There are no studies from Africa, and
none have compared oral antibiotics with injectable therapy for management of infants with fast breathing as the only sign of illness. Thus,
there is a need to inform policy by providing evidence whether young
infants with fast breathing alone can be treated with oral antibiotics.
Such a study is being undertaken in the multicenter African sites.
TABLE 1. Comparison of WHO Integrated
Management of Neonatal Child Illness Algorithm and
Case Definition of Clinically Diagnosed Infection Used in
the Young Infant Simplified Antibiotic Therapy Trials
WHO Integrated Management of
Neonatal Child Illness Algorithm
History of convulsions or convulsions
Respiratory rate ≥60/min
Severe chest indrawing
Axillary temperature 37.5°C or
above (>99.5°F or above)
Axillary temperature <95.9°F
(<35.5°C)
Movement only when stimulated
or no movement at all
Not feeding well

Diagnostic Algorithm Used
in Simplified Antibiotic
Therapy Trials
Case Definition of Clinically
Severe Infections (CSIs)
—
—
Severe chest indrawing
Axillary temperature
≥100.4°F (≥38.0°C)
Axillary temperature
≤95.9°F (≤35.5°C)
Movement only with
stimulation
Feeding difficulty, confirmed
by feeding observation or
documentation of poor suck
on examination if mother
unavailable (Asian sites)
Stopped feeding well/feeding problems confirmed by
observation of infant feeding (African sites)

– indicates convulsions and fast respiratory rate are not included in the case definition of severe infection used in these trials.

© 2013 WHO, USAID, and BMGF
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CHOICE OF ANTIBIOTICS, REGIMENS, DOSAGE,
DURATION AND DELIVERY STRATEGIES
Ideally, the selection of an appropriate antimicrobial agent is
based on its ability to kill bacteria that are responsible for the infection
in the majority of cases, based on efficacy and safety data, and pharmacokinetic information from relevant pediatric age groups.26 For the
simplified antibiotic therapy trials, additional considerations include
ease of delivery in community settings and cost—both factors with
significant implications for future scale-up. The experimental arms,
therefore, comprise combinations of injectable and oral antibiotics or
switch therapy from injectable to oral antibiotics (Tables 2 and 3).
Penicillin and gentamicin are used globally for treating sepsis and presumed sepsis in the neonatal age group and the second
month of life.15,27,28 Extended-interval (24-hourly) gentamicin regimens using doses ranging from 4 to 5 mg/kg/day have been shown
to be as effective as traditional dosing regimens for treating neonatal
sepsis.29–31 The combination of penicillin/amoxicillin and gentamicin
targets common neonatal pathogens such as Escherichia coli, other
enteric gram-negative rods, streptococci and pneumococci.
Benzyl penicillin and ampicillin need to be given 4 times a day,
which is impractical in the outpatient setting. Based on recommendations from the 2007 London consultation on community-based strategies for management of severe infections in young infants born in high
mortality settings,12 the pharmacologic profile of antibiotics32,33 and
experience of their use,3–5 we decided to use a combination of procaine
penicillin and gentamicin delivered by intramuscular (IM) injection as
the reference arm to treat clinically diagnosed severe infection because
both can be given in once daily dosing and together can successfully
treat vast majority of bacterial infections in young infants.
For the simplified experimental regimens, amoxicillin was
selected as the oral agent. Oral antibiotics have successfully been
used in community-based management of neonatal pneumonia,
resulting in significant reduction in pneumonia and overall neonatal mortality.6,24 There is extensive experience with use of oral
amoxicillin in newborns and young infants, and safety of this drug
is well-established in this age group.27,34 In full-term neonates, the
bioavailability of oral amoxicillin is high at approximately 80%.35
Similar serum amoxicillin concentrations were achieved in neonates in the first 4 days of life with intravenous and oral routes,
with the exception of the first 30 minutes after dosing when levels
were lower with oral administration.36,37
All the simplified experimental arms in these studies employ
oral amoxicillin, yet in varying ways (Table 2). Arm D (injection gentamicin for 2 days and oral amoxicillin for 7 days) is being undertaken
only in the African sites because of reservations by the Technical
Advisory Group about achieving an adequate sample size in Pakistan
TABLE 2. Antibiotics Regimens Evaluated in Trials
of Simplified Antibiotic Therapy for Management of
Newborns and Young Infants With Clinically Diagnosed
Severe Infections (CSIs) or Fast Breathing
Reference arm
A – Daily injection procaine penicillin and gentamicin for 7 days.
Experimental arms
Clinically severe infections
  B – Oral amoxicillin twice daily and once daily injection gentamicin for 7 days.
  C – Daily injection gentamicin and procaine penicillin for 2 days,
followed by twice daily oral amoxicillin for additional 5 days.
  D – D
 aily injection gentamicin and twice daily oral amoxicillin
for 2 days, followed by oral amoxicillin for additional 5 days
(African sites only).
Fast breathing only
   E – Oral amoxicillin twice daily for 7 days.

© 2013 WHO, USAID, and BMGF

TABLE 3. Number of of Intramuscular (IM) Injections in
Each Therapeutic Arm
Arm A

Arm B

Arm C

Arm D

Arm E

14

7

4

2

0

Arm A: IM procaine penicillin and IM gentamicin for 7 days; Arm B: oral amoxicillin and IM gentamicin for 7 days; Arm C: IM procaine penicillin and IM gentamicin
for 2 days followed by oral amoxicillin; Arm D: oral amoxicillin and IM gentamicin for
2 days followed by oral amoxicillin; Arm E: oral amoxicillin alone in infants with only
fast breathing.

and Bangladesh within the funding period. The study comparing reference therapy with oral amoxicillin alone in infants who have only
fast breathing is also being conducted in African young infants.
Amoxicillin has been recommended for use in doses ranging
from 50 to 150 mg/kg/day. Higher doses are recommended to achieve
minimum inhibitory concentrations that can overcome pneumococcal resistance. High-dose oral amoxicillin (80–90 mg/kg/day) is the
therapy of choice for young children with otitis media and pneumonia due to suspected drug-resistant pneumococcal infection.38–40
The recommended intravenous dose of amoxicillin for neonates in
the first week of life is 100 mg/kg divided every 12 hours, whereas
150 mg/kg/day divided every 8 hours is recommended for older neonates.27 In the African and South Asian trials, amoxicillin is given
in doses ranging from 80 to 100 mg/kg/day based on 1 of 6 weight
bands in which the infant falls.
The duration of antibiotic therapy is based on achievement of
cure for an infection. The WHO recommendation of 10 or more days
duration of therapy for antibiotic treatment is not based on strong evidence. Studies in Bangladesh and India have used 10 days of antibiotic therapy,4,5 whereas in Pakistan, 7 days of procaine penicillin and
gentamicin once daily was found to be effective in the management
of possible serious bacterial infection in young infants when families
refused referral care.3 Very severe pneumonia in older children has
been treated with 7 days of injectable antibiotics with good results,41
whereas severe pneumonia has been treated with 5 days of oral antibiotics.42 Switch therapy of injectable to oral antibiotics has been demonstrated to be efficacious for treatment of serious infections in neonates18 and in older children.43 For young infants with clinical severe
infection included in this study, IM procaine penicillin will be used
in a dose of 50,000 units/kg once daily IM and IM gentamicin in a
4–7.5 mg/kg/day once daily dose IM (depending on weight band of
the young infant). Duration of all regimens in this study will be 7 days.
The trials are designed to be open-label because of the difficulty in ethically justifying use of placebo injections in the population under study and because acceptability of simplified regimens
with lower number of injections is an important secondary outcome
for the trials.

SELECTION CRITERIA FOR TRIAL PARTICIPANTS
AND TRIAL SITES
The current standard of care for young infants with clinical
signs suggestive of severe infection is hospitalization and parenteral antibiotic therapy for 10 or more days.23 As discussed elsewhere in this supplement44 and previously reported,4,45 this standard
of care is rarely practiced in developing countries with high neonatal mortality rates. For ethical reasons, in the design of these trials,
we felt compelled to only include sites where neonatal mortality
rates and hospitalization refusal rates were known to be high,8–10
and those young infants whose families refused referral advice for
hospitalization for their sick young infants. Documented refusal of
hospital admission thus forms an important inclusion criterion for
enrolment of study subjects. The Bangladesh and Pakistan investigators have reported their experience with family acceptance for
www.pidj.com |
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hospitalization.22,45 Other site characteristics are reported in the
site-specific articles in this supplement. The African trial sites in
Democratic Republic of Congo, Kenya and Nigeria were chosen
to be broadly representative of central, eastern and western subSaharan African countries with neonatal mortality rates exceeding
40 per 1000 live births and remote locations making access to hospital facilities difficult for many families.2
Despite the effect on study generalizability, we are excluding young infants with clinical signs of critical illness (unconscious,
convulsions, apnea, unable to feed, unable to cry, cyanosed, bulging fontanelle, persistent vomiting), infants with weight less than
1500 g and infants with surgical comorbidities because we cannot
ethically justify random allocation of such infants to therapeutic
options with oral antibiotics.

SELECTION OF PRIMARY STUDY OUTCOME
Treatment failure on or before 7 days of therapy has been
chosen as the primary study outcome in these trials and defined
as a composite of death, clinical deterioration, serious adverse
event, hospitalization or persistence of clinical signs beyond specified days. Death, although a hard outcome, has not by itself been
selected as a primary outcome because we expect the number of
deaths to be low (around 2%) based on prior experience3 as rescue
therapy is going to be provided and it will be unethical to withhold
such therapy. Therefore, using the comparatively rare outcome of
death will inflate the sample size to unfeasible levels. Because of
the subjective nature of clinical signs of deterioration, their definitions and determination have been standardized across sites and are
described further in the site-specific articles.8–10

CONCLUSION
This article describes the scientific rationale for the study
designs of 3 trials of simplified antibiotic therapy for the management of clinically diagnosed severe infections and a trial of management of fast breathing in newborns and young infants currently
being conducted in Bangladesh, Pakistan, Democratic Republic of
Congo, Kenya and Nigeria. Although designed as independent studies, extensive collaboration between study sponsors and among study
investigators has resulted in harmonization of study protocols wherever possible, which will allow subsequent pooled analyses by providing sufficient power to address important policy questions regarding outcomes in subgroups such as newborns with early-onset sepsis,
and infants with multiple clinical signs (indicating more severe illness) versus single signs. These trials will inform the development
of policies and guidelines regarding community case management of
newborns and young infants with clinically diagnosed severe infections as well as for infants with fast breathing alone.
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